Sign In

Login

Password

Forgot Password ? Sign Up

Wirus brodawczaka ludzkiego (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Wirus brodawczaka ludzkiego" in Polish language version.

refsWebsite
Global rank Polish rank
5doi.org
2nd place
6th place
3nih.gov
4th place
7th place
3europa.eu
68th place
31st place
1hpv.pl
low place
low place
1scientificamerican.com
896th place
686th place
1mp.pl
8,738th place
165th place
1aap.org
low place
low place
1forumzdrowia.pl
low place
4,216th place

aap.org

doi.org

doi.org

  • D.M. Harper, E.L. Franco, C.M. Wheeler, A.B. Moscicki i inni. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. „Lancet”. 367 (9518), s. 1247–1255, 2006. DOI: 10.1016/S0140-6736(06)68439-0. PMID: 16631880. 
  • S.L. Giannini, E. Hanon, P. Moris, M. Van Mechelen i inni. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. „Vaccine”. 24 (33–34), s. 5937–5949, 2006. DOI: 10.1016/j.vaccine.2006.06.005. PMID: 16828940. 
  • L.R. Baden, G.D. Curfman, S. Morrissey, J.M. Drazen. Human papillomavirus vaccine-opportunity and challenge. „N Engl J Med”. 356 (19), s. 1990–1991, 2007. DOI: 10.1056/NEJMe078088. PMID: 17494932. 

dx.doi.org

europa.eu

ema.europa.eu

ec.europa.eu

forumzdrowia.pl

hpv.pl

  • Typy wirusów HPV, [w:] hpv.pl [online], MSD Polska Sp. z o.o. [dostęp 2016-07-15].

mp.pl

nih.gov

ncbi.nlm.nih.gov

  • D.M. Harper, E.L. Franco, C.M. Wheeler, A.B. Moscicki i inni. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. „Lancet”. 367 (9518), s. 1247–1255, 2006. DOI: 10.1016/S0140-6736(06)68439-0. PMID: 16631880. 
  • S.L. Giannini, E. Hanon, P. Moris, M. Van Mechelen i inni. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. „Vaccine”. 24 (33–34), s. 5937–5949, 2006. DOI: 10.1016/j.vaccine.2006.06.005. PMID: 16828940. 
  • L.R. Baden, G.D. Curfman, S. Morrissey, J.M. Drazen. Human papillomavirus vaccine-opportunity and challenge. „N Engl J Med”. 356 (19), s. 1990–1991, 2007. DOI: 10.1056/NEJMe078088. PMID: 17494932. 

scientificamerican.com